country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-P99648A

Copy Link Print Information

Gosuranemab (powder)

(Synonyms: BMS-986168 (powder); IPN007 (powder); BIIB092 (powder))

Gosuranemab (BMS-986168; IPN007; BIIB092) (powder) is a humanised IgG4 anti-tau monoclonal antibody. Gosuranemab (powder) neutralizes the extracellular tau protein, inhibiting the spread and aggregation of pathological tau protein. Gosuranemab (powder) can be used for the research of progressive supranuclear palsy and early Alzheimer’s disease.

For research use only. We do not sell to patients.

CAS No.: 1788032-39-2

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Gosuranemab (powder) Chemical Structure

CAS No.: 1788032-39-2

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- In Vitro
- In Vivo
- Format
Chemical Information
Purity & Documentation
References
Calculators
Help & FAQs
Bioz

Biological Activity

Description

In Vitro

Gosuranemab (powder) exhibits high binding affinity to monomeric and aggregated tau and removes seeding-competent tau from AD brain lysate^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Gosuranemab (powder) (murine version IPN002; weekly; 8 weeks) reduces unbound tau levels in the cerebrospinal fluid and interstitial fluid of rTg4510 tauopathy transgenic mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

rTg4510^[1]
Dosage:

murine version IPN002
Administration:

weekly; 8 weeks
Result:

Reduced levels of unbound tau in cerebrospinal fluid (CSF) and interstitial fluid (ISF) at 57 days post-treatment initiation.

Format

IgG4-kappa

Chemical Information

CAS No. 1788032-39-2
Synonyms

BMS-986168 (powder); IPN007 (powder); BIIB092 (powder)
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Inhibitory Antibodies User Guide (603 KB)

References

[1]. Dam T, et al. Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial. Nat Med. 2021;27(8):1451-1457. [Content Brief]

[2]. Shulman M, et al. TANGO: a placebo-controlled randomized phase 2 study of efficacy and safety of the anti-tau monoclonal antibody gosuranemab in early Alzheimer's disease. Nat Aging. 2023;3(12):1591-1601. [Content Brief]

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

100 mg

Get Quote In-stock